- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 08.09. | Roivant surges on 'exceptional' results; Bristol Myers touts first-of-its-kind CAR-T therapy | ||
| 08.09. | Moonwalk reloads with $70M and new RNAi prospects for obesity | ||
| 08.09. | Novartis RNA drug falls short in rare muscle disease study | ||
| 08.09. | BrainChild hauls in $116M to make cell therapies for childhood brain cancers | ||
| 04.09. | Trailing rivals, AbbVie scores win with dual-acting myeloma drug | ||
| 04.09. | This week in charts: China deals, stock flatlines and Lilly's M&A spree | ||
| 04.09. | Ionis' rare neurology drug approved; Pfizer inks an ADC deal | ||
| 03.09. | An AI drug specialist zeroes in on rare forms of obesity | ||
| 03.09. | GSK wagers up to $1.3B on a different kind of cancer drug | ||
| 03.09. | Akeso, Summit cancer drug confirms lung cancer survival benefit | ||
| 03.09. | Ultragenyx to weigh 'significant' cost cuts as Angelman drug fails key study | ||
| 03.09. | The hidden scale-out problem behind CAR-T's growth | ||
| 02.09. | Autoimmune CAR-T faces tough questions after Novartis, Bristol Myers study halts | ||
| 02.09. | UniQure, after setbacks, seeks FDA approval of Huntington's gene therapy | ||
| 02.09. | Teva claims success in celiac study; BioMarin, Ascendis settle patent dispute | ||
| 01.09. | Mid-cap biotechs join Trump's latest round of drug pricing deals | ||
| 01.09. | Novartis says MS pill succeeds in two large studies | ||
| 01.09. | Alumis' TYK2 drug fails in key lupus study | ||
| 01.09. | Novartis, Bristol Myers pause autoimmune CAR-T trials due to safety concerns | ||
| 31.08. | FDA OKs Takeda, Protagonist drug for rare blood cancer | ||
| 31.08. | Lilly adds to immune drug pipeline with $2.9B Merida buyout | ||
| 31.08. | ESC '26: Cytokinetics' sell-off, Arrowhead's edge and a heart drug autopsy | ||
| 31.08. | The next frontier: Advancing foundation models with multimodal data | ||
| 28.08. | Moderna raises $2.6B to support cancer work; FDA clears updated COVID vaccines | ||
| 28.08. | AstraZeneca, Ionis data spark debate about RNA drugs' impact on deadly heart disease |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.